Stem cell addback to prevent infections after transplant
Part of Blood & lymphatic, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a disease that can be cured with a stem cell transplant.
- You are 25 years old or younger.
- You do not have a fully matched sibling donor available.
- You have a suitable related or unrelated donor (at least half-matched).
- You are not receiving a drug called alemtuzumab as part of your transplant preparation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests a way to lower the risk of graft-versus-host disease (GVHD), a common complication after a bone marrow transplant, by removing certain immune cells from the donor's stem cells before giving them to the patient. It is for young children with non-cancerous blood or immune diseases who need a transplant.
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.